Exit Pathways for Foreign Investors: IPO, M&A, and Secondary Markets Compared

The IPO exit — historically the marquee outcome for China venture investors — has become both slower and more geographically fragmented, but one specific and often-misunderstood risk within it has actually been formally resolved. On August 26, 2022, the PCAOB signed a Statement of Protocol with the China Securities Regulatory Commission and China's Ministry of Finance, establishing a framework for the PCAOB to fully inspect and investigate audit firms headquartered in mainland China and Hong Kong — a step taken specifically to prevent the forced delisting of over 200 US-listed China-based companies under the Holding Foreign Companies Accountable Act. The agreement worked as designed: the PCAOB completed on-site inspection fieldwork in China and Hong Kong before year-end, reported obtaining complete access to requested documents and testimony with no observed non-compliance, and on December 15, 2022 formally vacated its prior 2021 determinations that had put those 200-plus companies on a delisting track.

The practical upshot is that the acute, existential HFCAA delisting risk that dominated China ADR discussion through 2021–2022 is, as a matter of formal regulatory record, resolved — but residual investor caution persists at a level greater than the pre-2021 baseline, and US listing underwriting for new Chinese IPO candidates remains more conservative than it was before the episode, even without an active legal threat hanging over it.

Trade sale exits (acquisition by a strategic buyer, often a larger domestic technology company) remain a theoretically available pathway and, in some sectors, the more realistic one given depressed IPO valuations — but domestic strategic acquirers themselves have faced their own capital constraints and heightened antitrust scrutiny under SAMR since the 2020–2021 platform-economy crackdown (the same enforcement regime that produced Alibaba's ¥18.23 billion antitrust fine, discussed in a related fact), which has made large-scale technology M&A slower and more heavily reviewed than in the pre-2020 environment when Alibaba and Tencent-affiliated entities were prolific acquirers.

Secondary sales of private shares to other investors remain the most flexible pathway in principle but the thinnest in practice — China's private secondary market lacks the depth and standardized transaction infrastructure that has developed in the US venture ecosystem, meaning pricing discovery is harder, transaction timelines are longer, and finding a willing counterparty at a fair price requires more direct relationship-based sourcing than a mature secondary marketplace would provide.

The HFCAA episode is worth studying even now that its acute phase has passed, because it is a clean case study in exactly the kind of geopolitical exit risk this entire series is concerned with: a US-listed exit pathway for foreign capital in China went, within roughly two years, from routine to existentially threatened to formally restored — driven entirely by a bilateral regulatory dispute unrelated to any individual company's business performance. The companies best positioned to weather that episode were the ones that had already diversified their listing exposure (via the dual-listing pattern discussed in a related fact on STAR Market and Hong Kong listings), not the ones that simply waited for the dispute to resolve in their favor.

Given everything above, a realistic, well-run China exit process in 2026 typically begins tracking listing-readiness across multiple venues in parallel from at least 18–24 months before a targeted exit date, rather than committing to a single venue early and hoping conditions remain favorable. This means maintaining audit and financial-reporting quality sufficient for either an A-share, STAR Market, or Hong Kong listing standard simultaneously (the highest common denominator, since retrofitting weaker financial controls onto a higher standard late in the process is far costlier than building to it from the start), engaging both mainland and Hong Kong-qualified legal counsel early enough to structure the eventual holding-company layer correctly for whichever venue is ultimately chosen, and treating the specific CSRC or HKEX approval-queue pace at the time of filing (not at the time the exit was first planned) as the operative timeline assumption, given how much that pace has moved in the last several years alone.

Putting rough numbers on the qualitative comparison above: a STAR Market listing, from CSRC filing to actual trading debut, has historically run anywhere from roughly six months in the fastest, most favorable regulatory windows to well over two years when the approval queue is constrained (as it visibly was through 2024's sharp listing-volume pullback, discussed in a related fact); a Hong Kong Main Board listing under Chapter 18A or 18C has generally moved somewhat faster given its registration-oriented process design, though still commonly taking twelve to eighteen months from formal application to listing once a company is genuinely ready; and a well-structured trade sale to a strategic acquirer, once a willing buyer is identified, can in principle close faster than either listing route — but finding that willing buyer, given the antitrust-driven M&A slowdown discussed above, is itself frequently the longer and less predictable part of that pathway. These are directional planning benchmarks, not guarantees, and should be revisited against the prevailing regulatory pace at the time a specific exit is actually being planned.